anti-CD3/HER2 bispecific antibodies (Genmab)

N/A

Report date: 2026/03/19 16:53:45

Base Information

Drug Nameanti-CD3/HER2 bispecific antibodies (Genmab)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsT cell surface glycoprotein CD3 inhibitors

TargetsReceptor protein-tyrosine kinase erbB-2T cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGenmab A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenmab A/S

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A